Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01712113 · ClinicalTrials.gov registry record · NA
Crossover Bioequivalence Study of Irbesartan 300 mg Tablets Under Fasted Conditions
A NA study, sponsored by Roxane Laboratories.
- Completed
- Registry status
- NA
- Development phase
- 33
- Enrollment target
NCT01712113 is a NA study that has completed, run by Roxane Laboratories. The registered enrollment target is 33 participants.
The verdict
NCT01712113, a NA study, has completed, sponsored by Roxane Laboratories.
- COMPLETED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
Study Summary
The objective of this study was to prove the bioequivalence of Roxane Laboratories' Irbesartan 300 mg Tablets under fasted conditions
Interventions
- DRUG Irbesartan
- DRUG Avapro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2007-08 |
| Est. Completion | 2007-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01712113
The ClinicalTrials.gov registry entry for NCT01712113 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roxane Laboratories, which has 93 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Irbesartan is the first listed.
NCT01712113 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01712113 about?
NCT01712113 is a clinical study titled "Crossover Bioequivalence Study of Irbesartan 300 mg Tablets Under Fasted Conditions". The objective of this study was to prove the bioequivalence of Roxane Laboratories' Irbesartan 300 mg Tablets under fasted conditions
What is the current status of trial NCT01712113?
This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2007-08. Estimated completion is 2007-08.
What interventions are being tested in trial NCT01712113?
The interventions under investigation include: Irbesartan (DRUG), Avapro (DRUG).
Who is sponsoring clinical trial NCT01712113?
This trial is sponsored by Roxane Laboratories, which has 93 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.